Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$2.38 -1.7%	$5.73	$1.89 ▼ $11.64	$57.08M	1.34	856,687 shs	1.57 million shs
PSTX Poseida Therapeutics	$9.50	$9.48	$2.32 ▼ $9.67	$928.85M	1.63	1.11 million shs	N/A
SRNE Sorrento Therapeutics	$0.00 -12.5%	$0.00	$0.00 ▼ $0.02	$772K	0.98	94,360 shs	28,876 shs
ZURA Zura Bio	$1.72 -9.9%	$1.18	$0.97 ▼ $5.07	$130.60M	-0.1	512,134 shs	714,061 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	-1.65%	+12.26%	-62.70%	-69.64%	-70.54%
PSTX Poseida Therapeutics	0.00%	0.00%	0.00%	0.00%	+210.46%
SRNE Sorrento Therapeutics	0.00%	+7.69%	-36.36%	+40.00%	-83.91%
ZURA Zura Bio	-9.95%	+32.31%	+52.21%	+15.44%	-50.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INMB INmune Bio	1.5835 of 5 stars	3.3	1.0	0.0	1.1	1.7	0.6
PSTX Poseida Therapeutics	0.4977 of 5 stars	1.0	0.0	4.6	0.6	0.8	0.0
SRNE Sorrento Therapeutics	0.5937 of 5 stars	0.0	1.0	4.3	0.6	0.0	0.0
ZURA Zura Bio	3.2668 of 5 stars	3.6	3.0	0.0	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	2.57	Moderate Buy	$18.40	673.11% Upside
PSTX Poseida Therapeutics	2.00	Hold	$9.50	N/A
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.13	Buy	$14.33	733.33% Upside

Current Analyst Ratings Breakdown

Latest PSTX, ZURA, INMB, and SRNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	$10K	5,612.04	N/A	N/A	$1.45 per share	1.64
PSTX Poseida Therapeutics	$150.86M	6.16	N/A	N/A	$1.08 per share	8.80
SRNE Sorrento Therapeutics	$60.32M	0.01	N/A	N/A	N/A	∞
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
PSTX Poseida Therapeutics	-$123.43M	-$0.63	N/A	N/A	N/A	-40.28%	-72.26%	-21.53%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest PSTX, ZURA, INMB, and SRNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ZURA Zura Bio	-$0.19	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
PSTX Poseida Therapeutics	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	2.64	2.64
PSTX Poseida Therapeutics	0.68	3.20	3.20
SRNE Sorrento Therapeutics	N/A	N/A	N/A
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
PSTX Poseida Therapeutics	46.87%
SRNE Sorrento Therapeutics	0.02%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	35.70%
PSTX Poseida Therapeutics	2.90%
SRNE Sorrento Therapeutics	2.60%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
PSTX Poseida Therapeutics	260	97.77 million	94.94 million	Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data
ZURA Zura Bio	3	68.38 million	53.26 million	Optionable

PSTX, ZURA, INMB, and SRNE Headlines

Recent News About These Companies

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Rating of "Buy" from Analysts

July 13, 2025 | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

July 13, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What Happened

July 10, 2025 | marketbeat.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.comS

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 25, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTX, ZURA, INMB, and SRNE Company Descriptions

INmune Bio NASDAQ:INMB

$2.38 -0.04 (-1.65%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$2.36 -0.02 (-0.84%)

As of 07/21/2025 07:53 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Sorrento Therapeutics NASDAQ:SRNE

$0.0014 0.00 (-12.50%)

As of 07/21/2025 03:54 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Zura Bio NASDAQ:ZURA

$1.72 -0.19 (-9.95%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.05 (+3.20%)

As of 07/21/2025 07:52 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time